abstract |
The present invention provides an anti-tumor immunotherapy method targeting PD-1H (VISTA). Specifically, the present invention provides immune cells or engineered immune cells in which the PD-1H gene is not expressed or knocked out, or the expression of the gene is silenced. The immune cells or engineered immune cells of the present invention have good tumor killing effect. |